http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101168235-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-81 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-494 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 |
| filingDate | 2010-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101168235-B1 |
| titleOfInvention | 4. Composition for the prevention and treatment of allergic diseases containing chlorotetrazolo [1,5-a] quinoxaline and its derivatives as an active ingredient |
| abstract | The present invention relates to the use of 4-chlorotetrazolo [1,5-a] quinoxaline compound of Formula 1 having an anti-allergic effect and derivatives thereof. 4-chlorotetrazolo [1,5-a] quinoxaline and its derivatives of the present invention inhibit the secretion of allergens caused by granule secretion from mast cells and at the same time the tumor necrosis factor alpha (TNF) involved in allergic reactions. -α) and interleukin-4 (IL-4) show the effect of inhibiting the production, the composition containing 4-chlorotetrazolo [1,5-a] quinoxaline and derivatives thereof of the present invention is obese without side effects It can be usefully used as medicines and functional cosmetics for the fundamental prevention and treatment of allergic diseases caused by cell-mediated. [Formula 1] |
| priorityDate | 2010-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 343.